To the Editor: In reporting the results of the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE), Marso et al. (Aug. 24 issue)1 report a lower risk of hypoglycemia among patients who received insulin degludec than among those who received insulin glargine, without significant differences in basal insulin doses, monitored plasma glucose or glycated hemoglobin levels, or concomitant medications. Although the use of prandial insulin was similar in the two groups, no information was provided on the actual doses administered. The distribution of risk factors . . .

中文翻译：

---

Degludec与甘精胰岛素在2型糖尿病中的安全性

致编者：Marso等人在报告比较胰岛素Degludec与胰岛素甘精胰岛素对2型糖尿病高心血管事件患者的心血管安全性的试验结果时。（8月24日发行）1报告说，接受胰岛素地格曲酮治疗的患者发生低血糖的风险要比接受甘精胰岛素的患者低，基础胰岛素剂量，监测的血糖或糖化血红蛋白水平或并用药物均无显着差异。尽管两组的餐前胰岛素使用相似，但未提供有关实际给药剂量的信息。危险因素的分布。。。